赛迪拉尼布通过上调IRF-1来增强MHC-I的转录
Jie Zhang1, Hongjie Guo1, Longsheng Wang1
1Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Biochemical pharmacology
|February 1, 2024
概括
赛迪拉尼布通过激活IRF-1通路,在瘤细胞中增强主要基因相容性复合物I类 (MHC-I) 表达. 这种上调增强了抗瘤免疫力,并改善了对免疫治疗的反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 减少主要基因相容性复合物I类 (MHC-I) 在瘤中的表达阻碍了细胞毒性T细胞的免疫识别.
- 恢复MHC-I表达是增强抗瘤免疫反应的关键策略.
研究的目的:
- 为了研究cediranib对瘤细胞中MHC-I表达的作用.
- 为了阐明基底的分子机制cediranib诱导的MHC-I上调.
- 评估cediranib与免疫治疗结合的治疗潜力.
主要方法:
- 基于细胞的查模型被用来识别可上调MHC-I的化合物.
- 赛迪拉尼布对MHC-I表达的影响在非小细胞肺癌 (NSCLC) 细胞系和患者衍生细胞中得到验证.
- 研究了涉及干扰素调节因子1 (IRF-1) 和STAT1酸化的分子机制.
- 在体内研究评估了MHC-I表达,CD8+T细胞透和抗PD-L1疗法的疗效.
主要成果:
- 塞迪拉尼布显著提高了各种肺癌细胞中MHC-I表达的调节.
- 通过cediranib对MHC-I的上调调节通过通过IRF-1进行转录调节来调节.
- 塞迪拉尼布激活STAT1酸化,导致IRF-1和随后的MHC-I转录的增加.
- 在体内,cediranib增强了MHC-I表达,增加了CD8+ T细胞透,并改善了抗PD-L1治疗结果.
结论:
- 塞迪拉尼布通过依赖STAT1-IRF-1的途径有效地增加瘤细胞中的MHC-I表达.
- 这种机制增强了抗瘤免疫监测和T细胞透.
- 赛迪拉尼布作为治疗剂有望提高癌症治疗中的免疫疗法疗效.
相关概念视频
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


